Iodine oral

Drug Profile

Iodine oral

Alternative Names: BPX 03; IoGen

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Symbollon Pharmaceuticals
  • Developer BioPharmX Corporation; Jacobson Resonance Enterprises; Symbollon Pharmaceuticals
  • Class Disinfectants; Halogens
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast pain
  • Discontinued Fibrocystic breast disorders; Solid tumours

Most Recent Events

  • 14 Nov 2007 Phase III development in fibrocystic breast disorders is ongoing
  • 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
  • 14 Jun 2005 Symbollon Pharmaceuticals has initiated enrolment in a pivotal phase III trial for Fibrocystic breast disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top